1422975-15-2

Upstream product

• 76-83-5 trityl chloride 
• 1422975-12-9 C₄₃H₅₁NO₆S 
• 88335-92-6 (1S,2R)-2-(methoxycarbonyl)cyclohexanecarboxylic acid 
• 1422975-11-8 C₄₄H₅₃NO₆S 
• 1422975-10-7 C₃₅H₄₁NO₃S 
• 924273-15-4 6-(S-tritylsulfanyl)-hexaneamine 
• 13149-00-3 1,2-cis-cyclohexanedicarboxylic anhydride 

Downstream Products

• 1422975-14-1 C₃₇H₅₇NO₇S 
• 1422975-19-6 C₃₇H₅₇NO₇S 

Relevant academic research and scientific papers

Sustained release composition of prostacyclin

The present invention relates to sustained release compositions of prostacyclin, as well as uses thereof, in particular for the prevention and/or treatment of pulmonary arterial hypertension.

Carrier-linked treprostinil prodrugs

The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).

CARRIER-LINKED TREPROSTINIL PRODRUGS

The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).

SUSTAINED RELEASE COMPOSITION OF PROSTACYCLIN

The present invention relates to sustained release compositions of prostacyclin, as well as uses thereof, in particular for the prevention and/or treatment of pulmonary arterial hypertension.